These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 16839270)

  • 41. Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy.
    Pedersen SR; Sørensen MR; Buus S; Christensen JP; Thomsen AR
    J Immunol; 2013 Oct; 191(7):3955-67. PubMed ID: 24018273
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.
    Hangalapura BN; Oosterhoff D; Gupta T; de Groot J; Wijnands PG; van Beusechem VW; den Haan J; Tüting T; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
    Vaccine; 2011 Mar; 29(12):2313-21. PubMed ID: 21272606
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer].
    Yang Q; Yang G; Wei L; Jia F; Wu M; Guo Y
    Zhonghua Yi Xue Za Zhi; 2002 Jun; 82(11):775-9. PubMed ID: 12126551
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice.
    Ribas A; Butterfield LH; Hu B; Dissette VB; Meng WS; Koh A; Andrews KJ; Lee M; Amar SN; Glaspy JA; McBride WH; Economou JS
    Cancer Res; 2000 Apr; 60(8):2218-24. PubMed ID: 10786687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma.
    Pullarkat V; Lee PP; Scotland R; Rubio V; Groshen S; Gee C; Lau R; Snively J; Sian S; Woulfe SL; Wolfe RA; Weber JS
    Clin Cancer Res; 2003 Apr; 9(4):1301-12. PubMed ID: 12684398
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Xenogeneic melanoma-related antigen elicits anti-tumor immune response, companied by autoimmune injury].
    Tan XH; Wan YH
    Zhonghua Yi Xue Za Zhi; 2005 Jun; 85(23):1596-600. PubMed ID: 16185524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes.
    Perricone MA; Smith KA; Claussen KA; Plog MS; Hempel DM; Roberts BL; St George JA; Kaplan JM
    J Immunother; 2004; 27(4):273-81. PubMed ID: 15235388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
    Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
    Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding Gp100 and granulocyte-macrophage colony-stimulating factor.
    Rakhmilevich AL; Imboden M; Hao Z; Macklin MD; Roberts T; Wright KM; Albertini MR; Yang NS; Sondel PM
    Clin Cancer Res; 2001 Apr; 7(4):952-61. PubMed ID: 11309346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100.
    Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X
    Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study.
    Imboden M; Shi F; Pugh TD; Freud AG; Thom NJ; Hank JA; Hao Z; Staelin ST; Sondel PM; Mahvi DM
    Hum Gene Ther; 2003 Jul; 14(11):1037-48. PubMed ID: 12885344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination of MIDGE-Th1 DNA vaccines with the cationic lipid SAINT-18: studies on formulation, biodistribution and vector clearance.
    Endmann A; Oswald D; Riede O; Talman EG; Vos RE; Schroff M; Kleuss C; Ruiters MH; Juhls C
    Vaccine; 2014 Jun; 32(27):3460-7. PubMed ID: 24681271
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.
    Mandelcorn-Monson RL; Shear NH; Yau E; Sambhara S; Barber BH; Spaner D; DeBenedette MA
    J Invest Dermatol; 2003 Sep; 121(3):550-6. PubMed ID: 12925214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Segregation of mechanisms for cytotoxic T lymphocyte killing between lungs and regional lymph nodes subsequent to intratracheal delivery of adenovirus 2 vector.
    Wang X; Hillemeyer P; Pascual DW
    Viral Immunol; 2003; 16(4):525-39. PubMed ID: 14733739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dynamic distribution and expression in vivo of the human interferon gamma gene delivered by adenoviral vector.
    Wu J; Xiao X; Jia H; Chen J; Zhu Y; Zhao P; Lin H; Huang W
    BMC Cancer; 2009 Feb; 9():55. PubMed ID: 19216804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonclinical safety assessment of repeated administration and biodistribution of ChAd3-EBO-Z Ebola candidate vaccine.
    Planty C; Chevalier G; Duclos MÈ; Chalmey C; Thirion-Delalande C; Sobry C; Steff AM; Destexhe E
    J Appl Toxicol; 2020 Jun; 40(6):748-762. PubMed ID: 31965598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use.
    Gu DL; Nguyen T; Gonzalez AM; Printz MA; Pierce GF; Sosnowski BA; Phillips ML; Chandler LA
    Mol Ther; 2004 May; 9(5):699-711. PubMed ID: 15120331
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression.
    Melo-Cardenas J; Urquiza M; Kipps TJ; Castro JE
    Cancer Gene Ther; 2012 May; 19(5):336-44. PubMed ID: 22402624
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine.
    Riede O; Seifert K; Oswald D; Endmann A; Hock C; Winkler A; Salguero FJ; Schroff M; Croft SL; Juhls C
    Gene Ther; 2015 Aug; 22(8):628-35. PubMed ID: 25871827
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells.
    Huang D; Pereboev AV; Korokhov N; He R; Larocque L; Gravel C; Jaentschke B; Tocchi M; Casley WL; Lemieux M; Curiel DT; Chen W; Li X
    Gene Ther; 2008 Feb; 15(4):298-308. PubMed ID: 18046426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.